Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stok Raporu

Piyasa değeri: US$3.6m

Cyclerion Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresino data
CEO sahipliğin/a
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO

Cyclerion Therapeutics CEO'su yok ya da onlar hakkında elimizde veri yok.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Peter Hecht
Director5.6yrsUS$169.80k15%
$ 547.2k
Errol De Souza
Independent Chairman3.6yrsUS$131.08k1.99%
$ 72.5k
Harald H. H. Schmidt
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Steven Hyman
Independent Director2.3yrsUS$57.30k0.79%
$ 29.0k
Michael Higgins
Independent Directorless than a yearUS$43.60k0.79%
$ 29.0k
Robert Malenka
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Daniela Salvemini
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78kVeri yok
Andrew Budson
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok
Eric Smith
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok
M Westover
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok
David Salat
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CYCN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).